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Abstract
Rabbits are widely used in biomedical research, yet techniques for their precise genetic modification are lacking. We
demonstrate that zinc finger nucleases (ZFNs) introduced into fertilized oocytes can inactivate a chosen gene by
mutagenesis and also mediate precise homologous recombination with a DNA gene-targeting vector to achieve the first
gene knockout and targeted sequence replacement in rabbits. Two ZFN pairs were designed that target the rabbit
immunoglobulin M (IgM) locus within exons 1 and 2. ZFN mRNAs were microinjected into pronuclear stage fertilized
oocytes. Founder animals carrying distinct mutated IgM alleles were identified and bred to produce offspring. Functional
knockout of the immunoglobulin heavy chain locus was confirmed by serum IgM and IgG deficiency and lack of IgM
+ and
IgG
+ B lymphocytes. We then tested whether ZFN expression would enable efficient targeted sequence replacement in
rabbit oocytes. ZFN mRNA was co-injected with a linear DNA vector designed to replace exon 1 of the IgM locus with
,1.9 kb of novel sequence. Double strand break induced targeted replacement occurred in up to 17% of embryos and in
18% of fetuses analyzed. Two major goals have been achieved. First, inactivation of the endogenous IgM locus, which is an
essential step for the production of therapeutic human polyclonal antibodies in the rabbit. Second, establishing efficient
targeted gene manipulation and homologous recombination in a refractory animal species. ZFN mediated genetic
engineering in the rabbit and other mammals opens new avenues of experimentation in immunology and many other
research fields.
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Introduction
Rabbits are important laboratory animals, widely used in many
areas of biomedical research, including the production of
antibodies and recombinant proteins. Rabbit models have
contributed to the understanding of human diseases and the
development of therapeutic compounds, devices and techniques.
However it has not been possible to engineer precise genetic
alterations in rabbits because they have so far been refractory to
the two key enabling technologies; (I) rabbit embryonic stem (ES)
cells capable of contributing to the germ line have yet to be
derived, and (II) rabbits are particularly difficult to produce by
somatic cell nuclear transfer [1].
The power and facility of gene targeting in ES cells has made
the mouse by far the most intensively studied mammal [2].
Extending gene targeting to other species would deepen our
understanding of gene function and further the development of
many valuable biomedical applications, but the lack of fully
functional ES cells has been a long-standing obstacle.
Nuclear transfer from cultured somatic cells (SCNT) was
developed to circumvent the requirement for ES cells to generate
gene-targeted animals. This is, however, technically difficult, and
more than ten years since our first demonstration of targeting
COL1A1 in sheep [3], there are still few other examples: PRNP in
sheep, cattle and goats [4]–[6], GGTA1 in pigs [7], [8], IGH in
cattle and pigs [5], [9], [10], IGKC in pigs [11] and CFTR in
pigs [12].
Zinc-finger nucleases (ZFNs) are new tools that promise to
radically simplify gene knockout and targeted gene replacement.
An appropriately designed ZFN can create a double-strand break
at a single predetermined site in the genomic DNA of an organism.
In eukaryotes, double-strand break repair pathways often create
small insertions and deletions at the break site, a useful means of
inactivating genes of interest (for review, see Urnov et al. [13]).
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exchange between an episomal donor construct and a chromo-
somal locus, as first demonstrated for a native locus in Drosophila
[14] and for endogenous loci in human cells [15]–[17].
A particularly promising approach is ZFN-mediated gene
knockout directly in early embryos, because it offers a one-step
method without any cell intermediate, as shown for zebrafish [18],
[19], rats [20], [21] and mice [22]. Most recently, ZFN-mediated
gene targeting by homologous recombination has been achieved in
mice and rats [23], [24]. However ZFNs are likely to make their
greatest impact in species where classical means of gene targeting
are not available. Here we demonstrate that ZFNs enable precise
genetic engineering in a particularly intractable species.
Results
Given the failure of other techniques, we wished to investigate
whether ZFN technology offers a practical means of targeted gene
inactivation, addition or replacement in the rabbit. The immuno-
globulin M locus was chosen as a suitable target because
inactivation of endogenous immunoglobulins is a necessary first
step for the production of human antibodies in a human
immunoglobulin transgenic rabbit model.
ZFN design and validation
ZFNs directed against exons 1–4 of rabbit IgM (Figure S1) were
designed using an archive of pre-validated zinc finger modules as
described [14], [15], [17]–[20]. The ZFNs were ranked for activity
using a budding yeast based system previously shown to identify
nucleases active in editing endogenous loci in zebrafish and rat
[18], [20], and the highest-ranking ZFN for each exon was
selected for in-vivo use. Target sequence, structure and recognition
helices of the selected ZFNs are shown in Figure 1 A–C.
Establishment of rabbit oocyte microinjection conditions
The kinetics of ZFN activity in fertilized oocytes should be as
rapid as possible, preferably before the first cleavage, to ensure
that ZFN induced mutations are included in the germ line. ZFN
activity should also be transient, to avoid possible accumulation of
additional mutations in the developing embryo. In pilot experi-
ments we microinjected EGFP mRNA diluted in either EDTA
solution (0.1 mM, pH 8), or Tris/EDTA buffer (5 mM/0.1 mM,
pH 7.5) into one of the two pronuclei or the cytoplasm of fertilized
rabbit oocytes. Microinjection was verified in each oocyte by
observing slight swelling of the pronucleus, or disturbance in the
cytoplasm caused by solution streaming from the capillary. Of the
oocytes injected into the pronucleus, only those injected with Tris/
EDTA survived and developed further. Following cytoplasmic
injection, survival and development was better in embryos injected
with EDTA. Cytoplasmic microinjection of mRNA diluted in
EDTA also led to earlier onset and higher EGFP expression at
lower concentrations than pronuclear microinjection of mRNA in
Tris/EDTA (Table S1).
We then examined technical parameters that could affect
embryo viability and the levels of ZFN activity. These included
ZFN mRNA concentration, site of microinjection (cytoplasm or
pronucleus), and in vitro polyadenylation of mRNA. Injected
embryos were cultured in vitro and monitored visually for
development up to blastocyst stage. Exons 1 or 2 of the IgM
locus were then amplified from blastocysts by nested PCR. Results
indicated that: the optimal mRNA concentration range was
between 3 to 6 ng/ml; microinjection of non-polyadenylated
mRNA did not lead to effective mutagenesis; and microinjection
into the pronucleus did not lead to effective mutagenesis (shown
for exon 1 in Table S2). For gene inactivation experiments we
therefore microinjected a 1:1 mixture of polyadenylated mRNAs
coding for the two components of a ZFN heterodimer, diluted to a
total of 3 to 5 ng/ml in 0.1 mM EDTA, into the cytoplasm of
pronuclear stage fertilized rabbit oocytes.
Microinjection of ZFN mRNA produces rabbits mosaic at
the IgM locus
mRNA coding for ZFN pair 18255/18257 targeted to IgM
exon 1 (see Figure 1) was injected into 267 oocytes, 208 embryos
were transferred into recipients and 17 live offspring were born.
mRNA coding for ZFN pair 18276/18277 targeted to IgM exon 2
(see Figure 1) was injected into 259 oocytes, 212 embryos were
transferred into recipients, and 17 live offspring were also born.
Sequence analysis of the IgM locus in these 34 rabbits revealed
that six animals carried mutations in exon 1, and four had
mutations in exon 2. Eighteen stillborn rabbits were also analyzed.
Mutations at the IgM locus were detected in six animals (Table 1),
a similar proportion as observed in the live offspring. DNA
sequence analysis of live and stillborn rabbits revealed a variety of
mutations at the IgM locus, including deletions of 1 to 25 bp,
single base insertions, and combinations of small deletions and
insertions. Results are summarized in Figure 1D. Two live and one
stillborn animal were found to carry two independent mutations at
the IgM locus, suggesting that these were compound heterozy-
gotes.
ZFN induced mutant IgM alleles are transmitted through
the germline
Of the ten rabbits identified as carrying ZFN induced mutant
IgM alleles, eight (four males and four females) survived to sexual
maturity and were used as founders to produce a F1 generation.
Seven F0 rabbits transmitted mutant IgM alleles at frequencies
ranging from 1.3% to 50% (Table 1). Among these, one male
(22826) and one female (22821) both carried two independent
mutations. The female failed to pass on either mutation to the next
generation, but the male transmitted both mutations at a similar
rate, suggesting that founder rabbits had different degrees of
mosaicism.
IgM knockout rabbits are IgM and IgG deficient
In the immune response, the first antibodies to appear are of the
IgM class. IgG, IgA, or IgE are then generated from IgM via class-
switch recombination. Lack of IgM should therefore result in the
absence of other isotypes. To determine if this was the case in our
rabbits, we generated IgM knockout rabbits by breeding ZFN-
treated founders and measured both IgM and IgG in serum.
The D1 (male founder 22826) and D7 (female founder 22830)
mutations in exon 1 both result in frameshifts in the IgM coding
region and were predicted to disrupt expression of full-length
protein. The founder male 22826 was intercrossed with the
founder female 22830 to generate D1/D7 compound heterozygous
animals. Three mutated F1 animals were obtained, one carrying
the D1 mutation, one carrying the D7 mutation, and one D1/D7
compound heterozygote. The D7 mutation was also bred to
homozygosity in an F2 generation. Serum IgM and IgG levels in
these animals were determined by ELISA at 10 weeks of age. IgM
and IgG levels were similar to wild type in D1 and D7
heterozygotes, but were undetectable in D1/D7 and D7/D7
rabbits (Table 2). The peripheral B-cell population in D1/D7 and
D7/D7 rabbits was characterized by FACS analysis; only ,0.1%
of PBMCs stained positive for surface IgM (sIgM), and sIgG
positive PBMCs were completely absent. In contrast, control wild
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positive for sIgG, typical for rabbit blood. A rabbit pan B-cell
specific antibody [25] also revealed significantly fewer stained cells
in the D1/D7 animal (1.5%) than in wild type (22.9%), see Figure 2
A and B. A second and well-defined B cell-specific marker is
CD79a, constituting a part of the B cell receptor. Using an
antibody that binds to the highly conserved intracellular domain of
CD79a [26], no B cell receptor positive cells could be detected in
D1/D7 and D7/D7 rabbits, whereas 41.4% of all PBMCs were
marked as B cells in control animals (Figure 2 C).
The founder 22826 (D1 mutation) was also crossed with founder
25035, which carries a D15 deletion in exon 2 predicted to result
in an in-frame loss of 5 amino acids. Serum analysis of D1/D15 F1
offspring revealed normal levels of IgM and IgG (Table 2). Thus,
the D15 mutation does not appear to affect functional IgM
expression or B-cell development.
These results show that ZFN-induced knockout alleles of the
rabbit IgM gene transmit normally through the germline, and in
homozygousform result inanimals that areIgM- and IgG-deficient,
but otherwise do not display obvious phenotypic abnormalities. It
Figure 1. ZFN-mediated disruption of rabbit IgM. A. Recognition sequences in the rabbit IgM locus for ZFNs used in this study. B. Screening
data using a budding yeast proxy system (see Materials and Methods) for ZFNs shown in panel A. The first sample represents positive control ZFNs
that target the human CCR5 locus [51]. The grey and black bars represent reporter gene correction levels at low and high levels of ZFN synthesis,
respectively. As detailed in Doyon et al. [18], the ZFN-encoding transgene is inducible, and this allows measurement of ZFN activity at different levels
of the nuclease. C. DNA target sequences and recognition helices for the ZFNs used in the present work. The binding regions of left (ZFN-L) and right
(ZFN-R) zinc finger protein array are underlined. Bases in capital letters are those that contribute to binding of the ZFP arrays. D. Summary of rabbit
IgM mutant alleles obtained and characterized in offspring from ZFN microinjections. Stillborn animals are marked with an asterisk. The genotype of
each allele is indicated to the right of the DNA sequence; inserted sequences are highlighted in red.
doi:10.1371/journal.pone.0021045.g001
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overall immunological function in these rabbits.
ZFN-mediated targeted sequence replacement
We then tested if ZFN-mediated targeted sequence replacement
was feasible directly in the oocyte. A gene targeting vector, IgME1,
was designed to replace IgM exon 1 with a PGK neo cassette,
providing ,1.9 kb of novel sequence. The strategy is illustrated in
Figure 3; the full sequence of the gene-targeting vector is shown in
Figure S2. Although the presence of the PGK neo gene was used
for screening, no antibiotic selection was used to enrich for neo-
positive embryos.
Mixtures of MluI linearised IgME1 DNA (concentrations ranging
from 5 to 15 ng/ml) and ZFN 18255/18257 mRNAs (concentra-
tions ranging from 3 to 9 ng/ml of each) were injected into
pronuclear stage fertilized oocytes, see Table 3. Since ZFN mRNAs
are most effective when injected into the cytoplasm, but IgME1
targeting vector DNA must be located in the nucleus to serve as the
donor during homology-directed repair, we employed a two-step
microinjection procedure similar to that described by Meyer et al.
[23]. A portion of the mRNA/DNAmixture wasfirst injected intoa
pronucleus to locate the vector DNA with the nuclear DNA. Then,
on removing the injection needle, a second dose was injected into
the cytoplasm to enable translation of ZFN mRNA. Microinjected
oocytes were cultured to blastocyst stage and a total of 242
blastocysts were analyzed by PCR for targeted gene replacement
events. Correct gene editing was detected in three blastocysts, as
judged by the presence of a diagnostic 1.758 kb PCR product
spanning the 59 junction of the target site, see Figure 4. Data
summarized in Table 3 show that concentrations of ZFN mRNA
slightly higher than those used for mutagenesis were most effective
in driving targeted sequence replacement. Combined data for all
mRNA and targeting vector DNA concentrations indicated an
overallrateof1.2%targeted sequence replacement,butefficiencyat
the most effective mRNA/DNA concentrations was higher (17% at
9 ng/ml ZFN mRNA plus 10–15 ng/ml IgME1 DNA). Positive
blastocysts were also screened for the presence of an intact IgM
exon 1 by PCR. All gave a positive result, indicating that targeting
had occurred at just one IgM allele.
Oocytes were then injected with 9 ng/ml ZFN 18255/18257
mRNA plus 10 ng/ml IgME1 DNA, and transferred to recipients.
Seventeen fetuses were removed at day 15 of gestation and
analyzed. All showed normal development, and examination of the
uterine horns showed no evidence of degenerate or absorbed
conceptuses. DNA was prepared from each fetus and screened by
PCR. Three fetuses (2, 7 and 9) showed amplification of a 1.758 kb
product acrossthe59 junctionanda 1.683 kbfragmentacrossthe39
junction of the target site, consistent with replacement of IgM exon
1 with the PGK neo cassette by homologous recombination, see
Figure 4. The identity of the 59 PCR product was confirmed by
restriction digestion, see Figure 4. In addition, the DNA sequence of
the 59 PCR product from fetus 7 was determined and found to be
identical to that predicted for the targeted locus, see Figure S2.
Southern hybridization analysis was carried out using genomic
Table 1. Injection of ZFN-encoding mRNA into fertilized rabbit oocytes.
Target/
ZFN Pair Experiment
mRNA
conc.
(ng/ml)
Oocytes injected/
transferred
Oocytes per
recipient
Offspring
live/stillborn
F0 mutated
(% of live
offspring)
Mutations
in F0
Founder
(line) ID/
gender
Mutated/
total offs-
pring in F1 (%)
IgM exon
118255/18257
1 3 40/22 11 2/1 1 (50) D1; D25 22821/f 0/17u (0)
11 1/0 1 (100) D10 22822/f
#
2 3 133/120 30 5/0 1 (20) +11 (D7+18) 22823/m 1/80 (1.3)
30 0/9 4* (0) D5; D10; +1;
+5( D5+10)
30 7/2 3 (43) D10; D1 22826/m 21**/83 (25)
D10 22828/f
1
D7( D8+1) 22830/f 7/14 (50)
3 5 94/66 22 1/1 0 (0)
22 1/2 1* (0) D8; D13
22 0
IgM exon
218276/18277
4 3 96/75 20 1/0 1 (100) D16 24656/f 2/5 (40)
28 2/0 1 (50) D19 24657/m 5/16 (31)
27 0/2 1* (0) D15
5 3 27/25 25 0/1 0 (0)
6 3 136/112 28 0/0 0 (0)
28 6/0 0 (0)
28 6/0 1 (17) D15 25035/f 1/6 (17)
28 2/0 1 (50) +1 25039/m 2/13 (15)
*Stillborn.
uNo further breeding.
#Exitus at 14 weeks of age.
1Exitus at 19 weeks of age.
**10 offspring with 1 bp deletion; 11 offspring with 10 bp deletion.
doi:10.1371/journal.pone.0021045.t001
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The Southern blotting scheme is outlined in Figure 3 and results
shown in Figure S3. Each of the PCR positive fetuses showed
a diagnostic restriction fragment spanning the 39 junction of the
target site, consistent with targeted replacement at the first exon,
and also a fragment corresponding to a wild type IgM allele.
The five negative fetuses showed only the wild type allele.
In summary, our data show efficient ZFN-induced gene
disruption and homology-directed sequence replacement through
microinjection in rabbit oocytes. We have obtained the first
rabbits genetically engineered at a specific endogenous locus, the
immunoglobulin M locus.
Discussion
Gene targeting in ES cells has propelled the mouse to the
forefront of biomedical research. This is despite the fact that its
small size limits the scope for many physiological investigations
and the low blood volume precludes its use as a source of serum
factors. Metabolic and physiological differences also limit the
relevance of mice to some human diseases, e.g. cardiomyopathy
[27] or cystic fibrosis [12]. Other mammals, notably rabbit and
pig, are increasingly seen as valuable alternatives but there is a
significant need for efficient methods of precise genetic engineer-
ing in these species. Here we describe a generally applicable
protocol for targeted genome editing in the rabbit. ZFNs
introduced into fertilized oocytes can mediate gene inactivation
by DNA repair mutagenesis and also homology-directed targeted
sequence replacement. The technique is a simple, efficient and
practical means of establishing lines of precisely genetically
engineered rabbits.
Like mice, rabbits have a short generation time, produce large
numbers of offspring and can be raised under specific pathogen free
conditions. They have long been an important research animal, and
arean indispensible source of polyclonal and monoclonal antibodies
[28], [29]. Spontaneous mutant rabbit strains such as WHHL are
widely used in the study of lipid metabolism and atherosclerosis
[30]. Pronuclear microinjection of DNA is as facile in rabbits as in
mice, and transgenic rabbits have been generated as models for
retinal degeneration [31], cardiomyopathy [32], inflammation [33],
hyperlipidemia [34] and for the evaluation of human vaccines [35].
Rabbits have also been used for the production of pharmaceutical
proteins in milk. However, until now the scope of genetic
manipulations has been limited to gain-of-function changes by
classical random transgenesis.
Human polyclonal antisera produced by hyperimmunisation
of animals with a humanized immune system are potentially an
extremely useful new class of therapeutic agents. The inactiva-
tion of the IgM locus and loss of endogenous IgM and IgG
expression on B cells and in serum that we describe is an
essential step in the modification of rabbits to produce human
immunoglobulins. The expression of immunoglobulin trans-
genes has been described for pigs, chicken, and rabbits [36]–
[38], and recently the inactivation of immunoglobulin genes in
pigs was reported [10], [11]. However, the inactivation of
endogenous immunoglobulin genes in combination with addi-
tion of human immunoglobulin genes has so far only been
achieved in mice and cattle [9], [39]–[44]. Experiments are now
underway to achieve this in rabbits.
ZFN-mediated mutagenesis of the IgM locus in rabbit oocytes
was efficient, yielding up to 30% mutant animals in the founder
generation. Seven of eight founders passed on mutant alleles to
their progeny. We also assessed whether ZFN-mediated targeted
sequence replacement could be carried out directly in the oocyte
without subsequent selection for the desired event, as recently
described in mice [23]. Our results show targeted sequence
replacement in rabbit at a rate of up to 18% in fetuses. The
frequency of ZFN mediated homologous recombination events we
observed was therefore at least equal to that described in mouse
(1.7–4.5%, Meyer et al. [23]) and clearly higher than the rate of
approximately 1 in 500 reported in mouse zygotes without ZFN
[45]. These results suggest that the technique should be generally
applicable, opening the way for the full repertoire of sophisticated
gene replacement and modification techniques developed in
mouse ES cells. ZFN-mediated genome editing does not require
expression at the targeted locus and our data show that regions of
homology as short as 1 kb or less, easily obtained by PCR
amplification, are sufficient for efficient targeted sequence
replacement. With less than 2 kb of total homology, our IgM
gene targeting vector was considerably shorter than those
described by Meyer et al. [23], but similar to those used for
ZFN-mediated gene targeting in human transformed [16], ES and
iPS cells [46].
Rodents, rabbits and other mammals all have particular
limitations and strengths for biomedical research and are best
regarded as complementary. Parallel and comparative studies
performed in more than one species will speed progress in disease
research and provide more reliable evaluation of novel diagnostic
and therapeutic strategies. Gene targeting in ES cells is established
in mouse and now in rat [3], but has so far been elusive in rab
bit. Our approach circumvents the need for ES cells or SCNT to
carry out precise alterations in any gene, because ZFNs can be
designed against any native locus of interest [13], [47]. This
achievement removes a major block to the development of
Table 2. IgM and IgG serum levels at 10 weeks of age.
Parental lines Genotype of offspring Serum IgM (mg/ml) Serum IgG (mg/ml)
22830622826 D7, D1 bdl* bdl*
22830622826 D7, wt 2.7 1.4
22830622826 D1, wt 1.1 1.3
25035622826 D15, D1 1.5 0.9
22830622830 D7, D7 bdl* bdl*
Wild type (3 animals) wt, wt 2.2 1.8
1.7 5.7
2.2 0.9
*Below detection limit: ,500 ng/ml for rbIgM ELISA and ,20 ng/ml for rbIgG ELISA.
doi:10.1371/journal.pone.0021045.t002
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PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e21045Figure 2. Characterization of the peripheral B-cell compartment of mutant offspring from ZFN-treated rabbits by FACS analysis.
A. The top panels show representative dot plot profiles of peripheral blood mononuclear cells (PBMCs) of a wild type rabbit stained with antibodies
specific for surface IgM (left) and surface IgG (right). Lower panels show D1/D7 PBMCs stained with the same antibodies. B. The upper dot plot shows
wild type PBMCs immunostained with RACT30A, an antibody that recognizes a rabbit B-cell specific surface protein [25]. The lower panel shows
D1/D7 PBMCs stained the same way. A and B: Only live PBMCs were included in these analyses. C. Dot plot profiles showing wild type (left) and D7/D7
(right) PBMCs, stained intracellularly for the B cell receptor component CD79a. The percentage of gated B cells (IgM
+, IgG
+, rabbit B cell marker
+,o r
CD79a
+) of all PBMCs is indicated in the upper right of each dot plot.
doi:10.1371/journal.pone.0021045.g002
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SCNT technologies are not available. Furthermore, unlike ES cell-
based methods, the desired genetic change can be introduced
directly into the animal strain of choice, and heterozygous
individuals obtained in the first generation. We are confident that
this can be applied to other rabbit genes and other mammals,
including important livestock species such as pigs. The possible
applications are manifold.
Figure 3. Targeted sequence replacement at the IgM locus. The structure of the IgME1 gene targeting vector, regions of homology with the
IgM locus, and the predicted structure of the targeted locus are shown. Exons are marked and numbered as open boxes. The ZFN 18255/18257
cleavage site within exon 1 is indicated by a vertical arrow. The 59 and 39 junction PCR products are indicated; with positions of primers marked by
arrows, and restriction sites for MscI and ApaI marked by (M) and (A), respectively. The hybridization probe and the diagnostic fragments used for
Southern analysis are indicated in the lower part of the diagram. HinDIII (H) and BspHI (B) restriction sites are marked.
doi:10.1371/journal.pone.0021045.g003
Figure 4. PCR analysis of gene targeted blastocysts and fetuses. Upper panel, representative 59 junction PCR products amplified from
blastocysts. Upper panel left, 59 junction PCR from fetuses. Predicted 59 PCR fragment size: 1.758 kb. Upper panel right, restriction digests of 59 PCR
fragment amplified from fetus 7. Predicted restriction fragment sizes: ApaI - 1242, 516 bp; MscI - 853, 687, 219 bp. Middle and bottom panels, 59 and
39 junction PCR products amplified from fetuses 1–12. Predicted 39 PCR fragment size: 1.683 kb. M - size markers.
doi:10.1371/journal.pone.0021045.g004
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All animal experiments were approved by the Government of
Upper Bavaria (permit numbers 55.2-1-54-2531-26-04 and 55.2-
1-54-2531-9-09) and performed according to the European Union
Normative for Care and Use of Experimental Animals. Chemical
reagents were obtained from Sigma unless otherwise indicated.
Gene targeting vector
The vector IgME1, used for ZFN-mediated targeted replace-
ment, comprised a 0.758 kb homologous arm extending upstream
of IgM exon 1 on the 59 side, and a 1.035 kb arm extending
downstream of IgM exon 1 to the end of exon 3 on the 39 side,
separated by a PGK neo polyA cassette (see Figure 3 and Figure
S2). Homologous sequences were obtained by PCR from genomic
DNA from a ZIKA rabbit.
In-vitro mRNA transcription
Synthetic capped and poly A-tailed mRNAs were transcribed in
vitro and purified using mMESSAGE mMACHINE T7 Ultra and
MEGAclear Kits (Ambion). The quality and concentration of
mRNAs were verified by denaturing gel analysis and spectropho-
tometry.
Microinjection of ZFN mRNA and targeting vector DNA
Animals usedas oocyte donors for the gene inactivation experiments
were homozogous Alicia/homozogous Basilea back-crossed for several
generations onto the ZIKA background. Alicia (Ali) rabbits carry a
natural deletion within the IgH locus [48] and homozygous Basilea
(Bas) animals do not express Igk, due to a non-functional splice
acceptor [49]. ZIKA rabbits were used as oocyte donors for the gene
replacement experiments. Pronuclear stage fertilized oocytes were
obtained by flushing oviducts 21 to 24 hrs from female rabbits
superovulated by PMSG (Intergonan; Intervet) and hCG (Ovogest;
Intervet) injection, inseminated artificially or by natural cover.
Microinjected oocytes were either cultured to blastocyst stage,
or allowed to rest for 1 hr then transferred laparoscopically [50] to
foster mothers primed by intramuscular injection of 0.2 ml
Receptal (Intervet) 3 to 7 hrs previously. Pregnancies were either
terminated at day 15 to examine fetuses, or allowed to proceed to
term. Offspring were delivered normally and their genotype was
determined at approximately 3 weeks of age.
Detection of ZFN-induced gene inactivation and
homologous recombination at the IgM locus
DNA was prepared from blastocysts by lysis in 50 mM
KCl, 1.5 mM MgCl2, 10 mM Tris, pH 8.0, 0.5% NP40, 0.5%
Tween20 and 100 mg proteinase K; or by lysis in 8 ml5 0m M
NaOH (10 min 95uC; 2 ml 1 M Tris, pH 7.5 then added for
neutralization); and from fetal tissue or ear biopsies of offspring by
standard methods. Rabbit Cm was amplified by PCR using primer
pairs E1.1f (TGG CAG GGA CAC AGG AAA ACA) and E1.1r
(GGC TCA CCG GGA AAG GAC); or E1.2f (GGC TGC CTG
GCG CGG GAC TTT CT) and E1.2r (CTG TTG CTG TTG
CTG TGC TGG ACT TTG) for exon1 and E2.1f (GGC TGC
CTG GCG CGG GAC TTT C) and E2.1r (CCT GGC CTG
GGG ACT GGA CAC TCA CT) or E2.2f (TGC CAG GCC
ACA GGT TTC) and E2.2r (CTC GGA GGA CAT GGA CAC
GTT CTT ATC) for exon 2. Nested PCRs from blastocysts were
performed using the two primer pairs specific for exon 1 or 2
consecutively. PCR products containing mutated sequences
detected by DNA sequence chromatography were cloned into
the TOPO TA cloning kit (Invitrogen) for DNA sequencing of
ZFN-induced mutations.
Targeted insertion of the PGK neo gene was detected by PCR
across the 59 junction using primers targF4 (GCT GTA CAG
AGG TGA ACT GGG CTG GTC TTA) and targR4 (CCG
CTG TAA GTC TGC AGA AAT TGA TGA TCT) and across
the 39 junction using primers targF2 (CGG AGA ACC TGC
GTG CAA TCC ATC T) and targR2 (TGG GCA GAG AGA
AGG TGG TGA GCC T). Southern hybridization of 10 mg
samples of genomic DNA was performed with a digoxigenin
dUTP labeled probe and detected by chemiluminescence using
standard methods.
Detection of rabbit IgM and IgG in serum
Serum antibody concentrations from animals between 7 and 15
weeks of age were determined by ELISA on streptavidin pre-
coated 96 well microtiter plates (Micro Coat Biotechnologie,
Germany). Capture was by anti-rabbit-IgM (m-chain) or anti-
rabbit-IgG (Fc) biotin (624085 and 550326, BD Pharmingen);
detection used mouse anti-rabbit IgM or IgG horseradish
peroxidase (BD Pharmingen).
FACS analysis of peripheral blood mononuclear cells
(PBMCs) of wild type and knockout rabbits
PBMCs were isolated from whole blood samples using
separation media (Lympholyte-Mammal; Cedarlane) according
to the manufacturer’s instruction and stained and analysed
immediately. For single colour flow cytometry, 5610
5 PBMCs
were distributed as 50 ml aliquots in 1.5 ml tubes and kept on ice.
Anti-rabbit IgG FITC was obtained from AbD Serotec (Du ¨ssel-
dorf, Germany). Anti-rabbit IgM biotin was from BD Pharmingen
(San Diego, USA). FITC labelled streptavidin and anti-mouse IgM
Table 3. Screening of rabbit blastocysts for targeted gene replacement.
Concentration of
ZFN mRNA (ng/ml)
Concentration of
vector DNA (ng/ml)
Oocytes
injected
Blastocysts
screened
Blastocysts positive
for targeting
35 1 0 2 4 5 0
31 03 9 2 6 0
6 5 76 43 0
6 10 118 76 1
61 52 8 1 8 0
91 01 7 6 1
91 56 0 2 8 1
doi:10.1371/journal.pone.0021045.t003
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The monoclonal antibody RACT30A, which detects an uniden-
tified rabbit B-cell surface marker [25], was obtained from VMRD
(Pullman, USA). The PE-labelled antibody (clone HM47, BD
Pharmingen), which binds the highly conserved intracellular
domain of human CD79a (component of the B cell receptor)
cross-reacts with rabbit CD79a [26]. For intracellular staining,
PBMCs were fixed with Cytofix and permeabilised with Perm/
Wash (BD Pharmingen) as mentioned in the instructions from the
manufacturer. PBMC aliquots were incubated with 50 ml
fluorochrome labelled mAbs or streptavidin in PBS for 30 min
under rotation at 4uC in the dark. PBMCs were washed twice with
ice cold PBS, resuspended in ice cold PBS and subjected to FACS
analysis. For all surface staining, propidium iodide at a
concentration of 5 mg/ml (BD Pharmingen, USA) was added
prior to FACS analysis to discriminate between live and dead cells.
10,000 live PBMCs were analysed per sample. A FACSAria flow
cytometer equipped with a computer and FACSDiva software
(Becton Dickinson) was used to collect and analyse the data, FACS
gates used are shown in each panel of Figure 2.
Supporting Information
Figure S1 IgM sequence polymorphisms in different
rabbit strains. The DNA sequence of the genomic IgM locus in
14 rabbits was determined; 6 rabbits of the ZIKA strain, 2 of the
Alicia strain [48], which carry a mutation in the immunoglobulin
heavy chain locus, and 6 of mixed breed (NZW/ZIKA/Alicia)
carrying the Basilea [49] loss-of-function mutation at the
immunoglobulin kappa light chain locus, which is on a different
chromosome. Exon sequences are underlined (Exons: E1–E4).
Polymorphisms are shaded in grey (R: A or G; Y: C or T). Five
sequence polymorphisms were found in E1, two in E2, four in E3
and one in E4. The binding sites of the ZFNs used for
microinjection are highlighted in red.
(TIF)
Figure S2 DNA sequence of IgME-1 targeted locus. The
sequence of the IgME1 gene targeting vector is indicated by
highlights; the 59 and 39 homologous arms in yellow and the PGK
neo cassette in blue. The positions of primers used to amplify PCR
fragments across the 59 junction (targF4 and targR4) and across
the 39 junction (targF2 and targR2) are indicated. ApaI and MscI
restriction sites used to confirm the identity of the 59 PCR product
(shown in Figure 3) and the BspHI site used for Southern analysis
(Figure S3) are indicated.
(TIF)
Figure S3 Southern analysis of fetuses. Samples of
genomic DNA from 9 of the 17 fetuses recovered (numbers
indicated) were digested with BspHI and HinDIII and hybridized to
a probe comprising IgM exon 3, intron 3 and exon 4. Arrows
indicate positions of the diagnostic 5.911 kb HindIII-HindIII
fragment, derived from the wild type allele, and the 3.943 kb
HindIII-BspHI fragment, derived from the targeted allele.
(TIF)
Table S1 Microinjection of mRNA coding for EGFP.
1 Experiment.
(DOC)
Table S2 Microinjection of mRNAs coding for ZFN SBS
18257/18255. 4 Experiments (separated by double lines).
(DOC)
Acknowledgments
We would like to thank Daniela Buntefuß, Marco Friedrich, Janine Gabler,
Brigitte Huemer, Sabrina Kettenbach, Christoph Schu ¨hlmann, and the
Sangamo Production group for excellent technical assistance, Edward
Rebar, Beilin Zhang and Jeffrey Miller for assistance with ZFN design, and
Nicole Schu ¨ler and Frederic Schultz for expert work in cloning the DNA
vector for targeted gene replacement. We also thank Fyodor Urnov for
editorial input and Susan Abrahamson for helpful comments on the
manuscript.
Author Contributions
Conceived and designed the experiments: TF IST SO FR VL BZ AJK PG
AES JP. Performed the experiments: TF IST SO FR VL BZ OR AV LZ
SJ HN. Analyzed the data: TF IST SO FR VL BZ HN. Wrote the paper:
IST AJK PG AES JP.
References
1. Zakhartchenko V, Flisikowska T, Li S, Richter T, Wieland H, et al. (2011) Cell-
mediated transgenesis in rabbits: chimeric and nuclear transfer animals. Biol
Reprod 84: 229–37.
2. Capecchi MR (2005) Gene targeting in mice: functional analysis of the
mammalian genome for the twenty-first century. Nat Rev Genet 6: 507–12.
3. McCreath KJ, Howcroft J, Campbell KH, Colman A, Schnieke AE, et al. (2000)
Production of gene-targeted sheep by nuclear transfer from cultured somatic
cells. Nature 405: 1066–1069.
4. Denning C, Burl S, Ainslie A, Bracken J, Dinnyes A, et al. (2001) Deletion of the
alpha(1,3)galactosyl transferase (GGTA1) gene and the prion protein (PrP) gene
in sheep. Nat Biotechnol 19: 559–562.
5. Kuroiwa Y, Kasinathan P, Matsushita H, Sathiyaselan J, Sullivan EJ, et al.
(2004) Sequential targeting of the genes encoding immunoglobulin-m and prion
protein in cattle. Nat Genet 36: 775–780.
6. Yu G, Chen J, Yu H, Liu S, Chen J, et al. (2006) Functional disruption of the
prion protein gene in cloned goats. J Gen Virol 87: 1019–1027.
7. Dai Y, Vaught TD, Boone J, Chen SH, Phelps CJ, et al. (2002) Targeted
disruption of the alpha1, 3-galactosyltransferase gene in cloned pigs. Nat
Biotechnol 20: 251–255.
8. Lai L, Kolber-Simonds D, Park KW, Cheong HT, Greenstein JL, et al. (2002)
Production of alpha-1, 3-galactosyltransferase knockout pigs by nuclear transfer
cloning. Science 295: 1089–1092.
9. Kuroiwa Y, Kasinathan P, Sathiyaseelan T, Jiao JA, Matsushita H, et al. (2009)
Antigen-specific human polyclonal antibodies from hyperimmunized cattle. Nat
Biotechnol 27: 173–181.
1 0 . M e n d i c i n oM ,R a m s o o n d a rJ ,P h e l p sC ,V a u g h tT ,B a l lS ,e ta l .G e n e r a t i o n
of antibody- and B cell-deficient pigs by targeted disruption of the J-region
gene segment of the heavy chain locus. Transgenic Res, 2010 Sep 26. [Epub
ahead of print].
11. Ramsoondar J, Mendicino M, Phelps C, Vaught T, Ball S, et al. Targeted
disruption of the porcine immunoglobulin kappa light chain locus. Transgenic
Res, 2010 Sep 26. [Epub ahead of print].
12. Rogers CS, Hao Y, Rokhlina T, Samuel M, Stoltz DA, et al. (2008) Production
of CFTR-null and CFTR-DeltaF508 heterozygous pigs by adeno-associated
virus-mediated gene targeting and somatic cell nuclear transfer. J Clin Invest
118: 1571–1577.
13. Urnov FD, Rebar EJ, Holmes MC, Zhang HS, et al. (2010) Genome editing
with engineered zinc finger nucleases. Nat Rev Genet 11: 636–646.
14. Bibikova M, Beumer K, Trautman JK, Carroll D (2003) Enhancing gene
targeting with designed zinc finger nucleases. Science 300: 764.
15. Urnov FD, Miller JC, Lee YL, Beausejour CM, Rock JM, et al. (2005) Highly
efficient endogenous human gene correction using designed zinc-finger
nucleases. Nature 435: 646–651.
16. Moehle EA, Rock JM, Lee Y, Jouvenot Y, DeKelver RC, et al. (2007) Targeted
gene addition into a specified location in the human genome using designed zinc
finger nucleases. Proc Natl Acad Sci USA 104: 3055–3060.
17. Lombardo A, Genovese P, Beausejour M, Colleoni S, Lee Y, et al. (2007) Gene
editing in human stem cells using zinc finger nucleases and integrase-defective
lentiviral vector delivery. Nat Biotechnol 25: 1298–1306.
18. Doyon Y, McCammon JM, Miller JC, Faraji F, Ngo C, et al. (2008) Heritable
targeted gene disruption in zebrafish using designed zinc-finger nucleases. Nat
Biotechnol 26: 702–708.
19. Meng X, Noyes MB, Zhu LJ, Lawson ND, Wolfe SA (2008) Targeted gene
inactivation in zebrafish using engineered zinc-finger nucleases. Nat Biotechnol
26: 695–701.
20. Geurts AM, Cost GJ, Freyvert Y, Zeitler B, Miller JC, et al. (2009)
Knockout rats via embryo microinjection of zinc-finger nucleases. Science
325: 433.
ZFN IgM Knock Out and Homologous Recombination
PLoS ONE | www.plosone.org 9 June 2011 | Volume 6 | Issue 6 | e2104521. Mashimo T, Takizawa A, Voigt B, Yoshimi K, Hiai H, et al. (2010) Generation
of knockout rats with X-linked severe combined immunodeficiency (X-SCID)
using zinc-finger nucleases. PLoS One, Jan 25; 5(1): e8870.
22. Carbery ID, Ji D, Harrington A, Brown V, Weinstein EJ, et al. (2010) Targeted
Genome Modification in Mice Using Zinc Finger Nucleases. Genetics 186:
451–459.
23. Meyer M, Hrabe ´ de Angelis M, Wurst W, Ku ¨hn R (2010) Gene targeting by
homologous recombination in mouse zygotes mediated by zinc-finger nucleases.
Proc Natl Acad Sci USA 107: 15022–15026.
24. Cui X, Ji D, Fisher DA, Wu Y, Briner DM, et al. (2011) Targeted integration in
rat and mouse embryos with zinc-finger nucleases. Nat Biotechnol 29: 64–7.
25. Davis WC, Hamilton MJ (2008) Use of flow cytometry to develop and
characterize a set of monoclonal antibodies specific for rabbit leukocyte
differentiation molecules. J Vet Sci 9: 51–66.
26. Jasper PJ, Zhai SK, Kalis SL, Kingzette M, Knight KLB (2003) B lymphocyte
development in rabbit: progenitor B cells and waning of B lymphopoiesis.
J Immunol 171: 6372–6380.
27. Marian AJ (2005) On mice, rabbits, and human heart failure. Circulation 111:
2276–2279.
28. Groves DJ, Morris BA (2000) Veterinary sources of nonrodent monoclonal
antibodies: interspecific and intraspecific hybridomas. Hybridoma 19: 201–214.
29. Popkov M, Mage RG, Alexander CB, Thundivalappil S, Barbas CF, III, et al.
(2003) Rabbit immune repertoires as sources for therapeutic monoclonal
antibodies: the impact of kappa allotype-correlated variation in cysteine content
on antibody libraries selected by phage display. J Mol Biol 325: 325–335.
30. Shiomi M, Ito T (2009) The Watanabe heritable hyperlipidemic (WHHL)
rabbit, its characteristics and history of development: a tribute to the late Dr.
Yoshio Watanabe. Atherosclerosis 207: 1–7.
31. Kondo M, Sakai T, Komeima K, Kurimoto Y, Ueno S, et al. (2009) Generation
of a transgenic rabbit model of retinal degeneration. Invest Ophthalmol Vis Sci
50: 1371–1377.
32. Lombardi R, Rodriguez G, Chen SN, Ripplinger CM, Li W, et al. (2009)
Resolution of established cardiac hypertrophy and fibrosis and prevention of
systolic dysfunction in a transgenic rabbit model of human cardiomyopathy
through thiol-sensitive mechanisms. Circulation 119: 1398–1407.
33. Serhan CN, Jain A, Marleau S, Clish C, Kantarci A, et al. (2003) Reduced
inflammation and tissue damage in transgenic rabbits overexpressing 15-
lipoxygenase and endogenous anti-inflammatory lipid mediators. J Immunol
171: 6856–6865.
34. Koike T, Kitajima S, Yu Y, Li Y, Nishijima K, et al. (2009) Expression of human
apoAII in transgenic rabbits leads to dyslipidemia: a new model for combined
hyperlipidemia. Arterioscler Thromb Vasc Biol 29: 2047–2053.
35. Chentoufi AA, Dasgupta G, Christensen ND, Hu J, Choudhury ZS, et al. (2010)
A novel HLA (HLA-A*0201) transgenic rabbit model for preclinical evaluation
of human CD8+ T cell epitope-based vaccines against ocular herpes. J Immunol
184: 2561–2571.
36. Lo D, Pursel V, Linton PJ, Sandgren E, Behringer R, et al. (1991) Expression of
mouse IgA by transgenic mice, pigs and sheep. Eur J Immunol 21: 1001–1006.
37. Weidle UH, Lenz H, Brem G (1991) Genes encoding a mouse monoclonal
antibody are expressed in transgenic mice, rabbits and pigs. Gene 98: 185–191.
38. Kamihira M, Kawabe Y, Shindo T, Ono K, Esaka K, et al. (2009) Production of
chimeric monoclonal antibodies by genetically manipulated chickens.
J Biotechnol 141: 18–25.
39. Wagner SD, Williams GT, Larson T, Neuberger MS, Kitamura D, et al. (1994)
Antibodies generated from human immunoglobulin miniloci in transgenic mice.
Nucleic Acids Res 22: 1389–1393.
40. Lonberg N, Taylor LD, Harding FA, Trounstine M, Higgins KM, et al. (1994)
Antigen-specific human antibodies from mice comprising four distinct genetic
modifications. Nature 368: 856–859.
41. Mendez MJ, Green LL, Corvalan JR, Jia XC, Maynard-Currie CE, et al. (1997)
Functional transplant of megabase human immunoglobulin loci recapitulates
human antibody response in mice. Nat Genet 15: 146–156.
42. Nicholson IC, Zou X, Popov AV, Cook GP, Corps EM, et al. (1999) Antibody
repertoires of four- and five-feature translocus mice carrying human immuno-
globulin heavy chain and k and l light chain yeast artificial chromosomes.
J Immunol 163: 6898–6906.
43. Green LL (1999) Antibody engineering via genetic engineering of the mouse:
XenoMouse strains are a vehicle for the facile generation of therapeutic human
monoclonal antibodies. J Imm Meth 231: 11–23.
44. Ishida I, Tomizika K, Yoshida H, Tahara T, Takahashi N, et al. (2002)
Production of human monoclonal and polyclonal antibodies in TransChromo
animals. Cloning Stem Cells 4: 91–102.
45. Brinster RL, Braun RE, Lo D, Avarbock MR, Oram F, et al. (1989) Targeted
correction of a major histocompatibility class II E alpha gene by DNA
microinjected into mouse eggs. Proc Natl Acad Sci USA 86: 7087–7091.
46. Hockemeyer DD, Soldner F, Beard C, Gao Q, Mitalipova M, et al. (2009)
Efficient targeting of expressed and silent genes in human ESCs and iPSCs using
zinc-finger nucleases. Nat Biotechnol 27: 851–857.
47. Carroll D (2008) Progress and prospects: zinc-finger nucleases as gene therapy
agents. Gene Ther 15: 1463–1468.
48. Knight KL, Becker RS (1990) Molecular basis of the allelic inheritance of rabbit
immunoglobulin VH allotypes: implications for the generation of antibody
diversity. Cell 60: 963–970.
49. Lamoyi E, Mage RG (1985) Lack of K1b9 light chains in Basilea rabbits is
probably due to a mutation in an acceptor site for mRNA splicing. J Exp Med
162: 1149–1160.
50. Besenfelder U, Brem G (1993) Laparoscopic embryo transfer in rabbits. J Reprod
Fertil 99: 53–56.
51. Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, et al. (2008) Establishment
of HIV-1 resistance in CD4
+ T cells by genome editing using zinc-finger
nucleases. Nat Biotechnol 26: 808–816.
ZFN IgM Knock Out and Homologous Recombination
PLoS ONE | www.plosone.org 10 June 2011 | Volume 6 | Issue 6 | e21045